Regulatory affairs fin
-
Upload
marina-hurtado-mira -
Category
Business
-
view
674 -
download
4
description
Transcript of Regulatory affairs fin
Marina Hurtado MiraMarina Hurtado MiraRegulatory Affairs AssociateRegulatory Affairs Associate
•Regulatory Affairs Department
•Role Regulatory Affairs
•Marketing Approvals Ways
Centralised Procedure
Mutual Recognition Procedure
National Procedure
•Post-approval
•European Medicines Agency’s Role
•Evaluation by EMA
REGULATORY AFFAIRS DEPT
MAA – Marketing Authorization Application
Prepare and submit the documents to regulatory
agencies
To give strategic and technical advice to the
departments; production, QC dept, QA, price and r;
marketing…
ROLE OF RA
Marketing Approval Ways
Centralised Procedure (CP)Mutual Recognition (MRP) /
Decentralised Procedure (DCP)
National Procedure (NP)
Better resources utilisation
Harmonised scientific opinions
Harmonised information for doctors
Centralised Procedure
MA
SmPC
PL
Labelling
Invented name
HIV/AIDS, cancer, diabetes,
neurodegenerative diseases, auto-
immune and viral diseases;
medicines derived from:
-biotechnology processes
-advanced-therapy medicines, orphan
drugs
HIV/AIDS, cancer, diabetes,
neurodegenerative diseases, auto-
immune and viral diseases;
medicines derived from:
-biotechnology processes
-advanced-therapy medicines, orphan
drugs
OPTION APPLICATION
Mandatory
Mutual Recognition Procedure / MRP
National licensed approved 1 member State RMS
RMS: Reference Member StateCMS: Concerned Member State
During recognization ask others
countries to
recognise the positive
opinion
NATIONAL PROCEDURE / NP
Evaluation by AEMPS
Authorisation by AEMPS
New National Application / NNA
Dossier to AEMPS
Validation
Evaluation
Authorisation
RAEFAR Nees / eCTD
POST-APPROVALDevelopment of strategies
-changes to manufacturing process
-changes to product characteristics
-additional indications
Responses to the Agencies
Organisation for future issues
Discussion of variation strategies and timing
EMA
AGENCY’S
ROLEEvaluation of applications – efficient and transparent
Provision of Advice (optional)
Control of safety
Evaluation for orphan designation
Evaluation for Pediatrics investigations - PIP
Provide good and independient information
96 applications
EU is a Single for pharmaceuticals
The main scientific principle used in the evaluation of medicines is the benefit/ risk balance, based mainly on quality, efficacy and safety
Evaluation by the European Agency
Evaluation by the European Agency
Adopts an opinion
SCIENTIFIC COMMITTEES
CHMP
CVMP
COMP
HMPC
CP – PIP
ATC
Chairman
Vice Chairman
5 experts (area) co-opted members
1 per month
27 MS
Evaluation by the European Agency
CHMP Adopts an opinion “Day 210”
- Marketed or not
This opinion “ European Commission “ 270 days
- The ultimate authority for granting marketing
authorisations in the EU
Marketed 3 Years – Sunset Clause
Evaluation by the European Agency
Authorised
EPAR European Public Assesment Report
EPARBriefSmPC; PIL; Label Authorised products
http://www.emea.europa.eu/ema/
1MAA - EU1MAA - EU
1 MAA / 1 MAA / differents differents countriescountries
1 MAA /Country1 MAA /Country National ProcedureNational Procedure
MRPMRP DCPDCP
CPCP
Conflict; disputeConflict; dispute
ReferralReferral
PROCEDURES / REFERRAL
www.pharmatalents.es
You can find us in Pharma Talents / LinkedIn &
Follow us inTwitter @talentspharma